Literature DB >> 24561612

Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity.

Annemie Deiteren1, Joris G De Man1, Nathalie E Ruyssers1, Tom G Moreels2, Paul A Pelckmans2, Benedicte Y De Winter1.   

Abstract

OBJECTIVES: Substantial evidence implicates mast cells and their main constituent histamine in the pathogenesis of visceral hypersensitivity. We explored the specific contribution of histamine H4 (H4R) and H1 (H1R) receptors to visceral hypersensitivity in a postinflammatory rat model.
DESIGN: Trinitrobenzenesulfonic acid (TNBS)-colitis was monitored individually by colonoscopy: first on day 3 to confirm the presence of colitis and then every 4 days, starting from day 10, to monitor convalescence and determine the exact timepoint of endoscopic healing in each rat. Experiments were performed 3 days after endoscopic resolution of colitis. Visceral sensitivity was assessed by quantifying visceromotor responses (VMRs) to colorectal distension. Colonic mast cell numbers, histamine release and H4R and H1R mRNA expression were quantified. JNJ7777120 (H4R antagonist) and/or levocetirizine (H1R antagonist) were administered 30 min prior to VMR assessment or histamine release assay.
RESULTS: Postcolitis rats displayed a higher number of colonic mast cells, excessive histamine release and significantly enhanced VMRs. Heightened VMRs were dose-dependently reduced by JNJ7777120 and levocetirizine; combined administration of JNJ7777120 and levocetirizine potentiated the antinociceptive effect. In the colon, both H4R and H1R mRNA were present; in the dorsal root ganglia, only H1R mRNA was found. Only colonic H4R mRNA expression was increased in postcolitis rats. Excessive histamine release in postcolitis rats was attenuated by the highest dose of JNJ7777120.
CONCLUSIONS: H4R and H1R antagonists dose-dependently reduce and even normalise postinflammatory visceral hypersensitivity via different underlying mechanisms but with a synergistic effect. Both receptor subtypes represent promising targets for the treatment of postinflammatory visceral hypersensitivity. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  HISTAMINE; MAST CELLS; VISCERAL HYPERSENSITIVITY; VISCERAL NOCICEPTION

Mesh:

Substances:

Year:  2014        PMID: 24561612     DOI: 10.1136/gutjnl-2013-305870

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

Review 1.  Histamine H₄ receptors in the gastrointestinal tract.

Authors:  A Deiteren; J G De Man; P A Pelckmans; B Y De Winter
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 2.  Existing and emerging therapies for managing constipation and diarrhea.

Authors:  Adil E Bharucha; Mira M Wouters; Jan Tack
Journal:  Curr Opin Pharmacol       Date:  2017-11-21       Impact factor: 5.547

3.  Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome.

Authors:  Hannah Ceuleers; Nikita Hanning; Jelena Heirbaut; Samuel Van Remoortel; Jurgen Joossens; Pieter Van Der Veken; Sven M Francque; Michelle De Bruyn; Anne-Marie Lambeir; Joris G De Man; Jean-Pierre Timmermans; Koen Augustyns; Ingrid De Meester; Benedicte Y De Winter
Journal:  Br J Pharmacol       Date:  2018-07-23       Impact factor: 8.739

Review 4.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

5.  Spinal cord astrocyte P2X7Rs mediate the inhibitory effect of electroacupuncture on visceral hypersensitivity of rat with irritable bowel syndrome.

Authors:  Zhi-Jun Weng; Shi-Xiu Hu; Fang Zhang; Zhi-Ying Zhang; Yun Zhou; Min Zhao; Yan Huang; Yu-Hu Xin; Huan-Gan Wu; Hui-Rong Liu
Journal:  Purinergic Signal       Date:  2022-04-07       Impact factor: 3.765

6.  Cyclic analogues of α-conotoxin Vc1.1 inhibit colonic nociceptors and provide analgesia in a mouse model of chronic abdominal pain.

Authors:  Joel Castro; Luke Grundy; Annemie Deiteren; Andrea M Harrington; Tracey O'Donnell; Jessica Maddern; Jessi Moore; Sonia Garcia-Caraballo; Grigori Y Rychkov; Rilei Yu; Quentin Kaas; David J Craik; David J Adams; Stuart M Brierley
Journal:  Br J Pharmacol       Date:  2018-02-13       Impact factor: 8.739

7.  Granulocyte-colony-stimulating factor (G-CSF) signaling in spinal microglia drives visceral sensitization following colitis.

Authors:  Lilian Basso; Tamia K Lapointe; Mircea Iftinca; Candace Marsters; Morley D Hollenberg; Deborah M Kurrasch; Christophe Altier
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-02       Impact factor: 11.205

8.  P2X3 receptors mediate visceral hypersensitivity during acute chemically-induced colitis and in the post-inflammatory phase via different mechanisms of sensitization.

Authors:  Annemie Deiteren; Laura van der Linden; Anouk de Wit; Hannah Ceuleers; Roeland Buckinx; Jean-Pierre Timmermans; Tom G Moreels; Paul A Pelckmans; Joris G De Man; Benedicte Y De Winter
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

9.  Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats.

Authors:  Nikita Hanning; Michelle De Bruyn; Hannah Ceuleers; Tim Boogaerts; Maya Berg; Annemieke Smet; Heiko U De Schepper; Jurgen Joossens; Alexander L N van Nuijs; Joris G De Man; Koen Augustyns; Ingrid De Meester; Benedicte Y De Winter
Journal:  Pharmaceutics       Date:  2021-05-29       Impact factor: 6.321

Review 10.  Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection.

Authors:  K A Dvornikova; E Yu Bystrova; L P Churilov; A Lerner
Journal:  Mol Biol Rep       Date:  2021-07-22       Impact factor: 2.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.